INS and type 1 diabetes mellitus: Administration of rosiglitazone (4 mg twice daily) along with insulin to obese adults with T1D (average HbA1c 7.9%, BMI 33 kg/m2, diabetes duration 21 years) led to significant reductions in HbA1c, blood pressure, and cholesterol levels, without an increase in insulin requirements (367).